Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 16/20 | 0.72 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.60 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.60 |
| ▸ | STK4 | Q13043 | 4/20 | 0.58 |
| ▸ | STK3 | Q13188 | 4/20 | 0.58 |
| ▸ | MST1 | P26927 | 1/20 | 0.55 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854357 | 0.90 | LRRK2 (0.67) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854597 | 0.86 | LRRK2 (0.74) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854260 | 0.85 | ROCK2 (0.57) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854370 | 0.85 | ROCK2 (0.61) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854253 | 0.85 | LRRK2 (0.74) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854365 | 0.85 | LRRK2 (0.61) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854254 | 0.83 | ROCK2 (0.61) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854312 | 0.82 | LRRK2 (0.76) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854179 | 0.82 | LRRK2 (0.77) | LRRK2ROCK2ROCK1CDC42BPBSTK4 | |
| SCHEMBL16854284 | 0.82 | LRRK2 (0.72) | LRRK2ROCK2ROCK1CDC42BPBSTK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | claimed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | claimed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | claimed |
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015092592-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | LRRK2, PARK7, BRCA1 | LRRK2 1/4885ROCK2 505/4885ROCK1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.